Table 1.

Characteristics of the study population.

CharacteristicsPatients with EAControlsp*
No.4343
Female/male14/2914/291.000
Mean age, yrs, ± SD34.72 ± 6.8835.02 ± 6.470.834
IBD duration, mean yrs ± SD5.30 ± 2.54NANA
Arthritis duration, mean yrs ± SD3.14 ± 1.63NANA
BASDAI, mean ± SD3.39 ± 1.901.25 ± 0.33< 0.001
BASFI, mean ± SD3.56 ± 1.691.14 ± 0.820.008
BASMI, mean ± SD3.55 ± 1.891.22 ± 0.550.001
SSCAI, mean ± SD2.79 ± 1.751.33 ± 1.010.042
HBI, mean ± SD3.74 ± 2.071.22 ± 0.540.032
ESR, mm/h, mean ± SD (normal 10–20)30.49 ± 12.4518.44 ± 9.540.028
CRP, mg/dl, mean ± SD (normal < 5.00)5.39 ± 6.673.67 ± 2.580.041
SpA-related spondylodiscitis, no. (%)22 (30.55)2 (4.65)< 0.001
  No. lesions342< 0.001
Subset of arthritis
  Axial23NANA
  Axial and peripheral20NA
Subset of inflammatory bowel disease
  Ulcerative colitis26NANA
  Crohn disease17NA
No. lesions each level
  Cervical30< 0.001
  Dorsal100< 0.001
  Lumbar212< 0.001
  • ** p value by sample t-test. NA: not applicable; EA: enteropathic arthritis; IBD: inflammatory bowel disease; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; BASFI: Bath Ankylosing Spondylitis Functional Index; HBI: Harvey-Bradshaw Index; SCCAI: Simple Clinical Colitis Activity Index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SpA: spondyloarthritis.